GLP-1 Side Effects Timeline: Week-by-Week What to Expect

The first injection rarely produces much of anything. Patients often describe the first week as anticlimactic — a tiny dose, an unfamiliar pen, a small subcutaneous click, and then the unsettling realization that they expected to feel different and don't. The dose was designed to be sub-therapeutic. The body has not yet started adapting because there is, at that point, very little to adapt to.

Then somewhere in week three or four, things begin. The titration upward starts producing changes that are recognizable as the medication doing its work — and as the gastrointestinal system protesting the new instructions arriving from the gut hormone axis. Knowing what is coming, and when it tends to arrive, makes the experience meaningfully less alarming than going in blind.

What follows is a composite timeline based on the STEP and SURMOUNT trial data and on the clinical experience of prescribers managing thousands of titration courses. Individual variation is substantial — some patients sail through with minimal symptoms, others have a rougher passage through the first months. The pattern below is what is most common, not what is universal.

Weeks 1–4: the titration starts

Semaglutide for weight loss begins at 0.25mg weekly. This dose is below the therapeutic range for appetite suppression and was chosen specifically to introduce the medication gently. Most patients in the STEP 1 trial reported few or no side effects in the first two to three weeks.

When symptoms do appear, they are usually mild: faint nausea after eating, particularly after larger or higher-fat meals; a vague feeling of fullness that arrives earlier than expected; occasional mild fatigue; sometimes a slight headache. These tend to be tolerable and resolve within a few hours of onset.

By week four, the dose typically escalates to 0.5mg. The first noticeable changes in appetite often begin in this window — meals feel smaller satisfying, snacks feel less necessary, food noise begins to quiet. Side effects also become more apparent. Nausea is the most common complaint, usually peaking in the first 24–48 hours after the weekly injection and easing as the week progresses.

What helps in the first month

Smaller, more frequent meals work better than large ones. Greasy and fried foods amplify nausea — gastric emptying is slowed by the medication, and high-fat content compounds the delay. Hydration matters: patients who under-drink in the first weeks have more nausea, more constipation, and more fatigue. Slow, deliberate eating helps the satiety signaling work in your favor rather than producing the uncomfortable overshooting that comes from eating quickly past the new fullness threshold.

Weeks 5–8: the dose escalates, symptoms peak

This is typically the hardest phase of the titration. The dose climbs to 1mg in this window for most patients, and the cumulative effect of escalating GLP-1 receptor activation on the GI tract becomes more pronounced.

Nausea peaks. Around 40% of STEP 1 participants reported nausea during titration, most commonly in this 5–8 week window. The pattern is usually a 12–48 hour peak after each weekly injection, fading by mid-week. For most patients, nausea is moderate and manageable. For a meaningful minority, it is significant enough to consider dose pauses or slower titration schedules.

Constipation often becomes prominent in this phase. Slowed gastric emptying combined with reduced food intake produces less material moving through the intestine, less frequent bowel movements, and harder stools. Adequate fiber, hydration, and sometimes osmotic laxatives (magnesium oxide, polyethylene glycol) become important.

Vomiting affects a smaller subset of patients — roughly 15–20% experienced vomiting at some point during STEP 1 titration. When it occurs, it usually clusters in this 5–8 week window and improves with dose adjustments and dietary modifications.

Fatigue is reported by some patients during titration phases and tends to improve as the body adapts. Mechanisms are incompletely understood but likely involve a combination of caloric reduction, GI symptoms, and the metabolic shift the medication produces.

Red flag symptoms in this window

Most symptoms in weeks 5–8 are uncomfortable but expected. A short list warrants immediate clinician contact regardless of timing:

Severe abdominal pain, particularly if radiating to the back, can be a sign of pancreatitis. GLP-1 medications are associated with a small increased risk and the symptom requires urgent evaluation.

Persistent vomiting that prevents fluid intake creates dehydration risk and may warrant dose pause and clinical assessment.

Signs of gallbladder disease — right upper quadrant pain, jaundice, persistent severe nausea — also require evaluation. Rapid weight loss increases gallstone risk independent of the medication.

Weeks 9–16: continued titration, symptoms ease

Through this window, the dose typically climbs to 1.7mg and then to the 2.4mg maintenance dose. Counterintuitively, side effects often improve in this phase even as the dose increases. The body has adapted to GLP-1 receptor activation, the GI tract has accommodated to slower gastric emptying, and the dietary patterns that minimize symptoms (smaller meals, lower fat, adequate hydration) have become habitual.

Nausea, when it persists, tends to be milder and less disruptive. Many patients report it largely resolving by week 12–16. Constipation often becomes the more persistent issue and remains a chronic management concern for some.

Appetite suppression deepens through this window. Patients describe meals becoming substantially smaller, hunger between meals largely absent, and food noise quieting in a way that feels qualitatively different from earlier diet attempts. The weight loss curve also accelerates — most STEP 1 patients saw their steepest rate of loss between months three and nine.

What patients sometimes find harder than expected

Social eating becomes complicated. Restaurant portions feel enormous. Buffets and large family meals can produce real distress as the body protests the volume it once accepted. Some patients describe a period of mourning around food — favorite dishes lose appeal, the rituals of celebration around eating shift, and the social architecture that had been built around food requires renegotiation.

Some patients also report mood changes during this window. The data on mood and GLP-1 medications is mixed and individual variability is substantial. Most patients report mood neutral or improved on therapy, but a subset describe low mood, decreased motivation, or — rarely — increased anxiety. These warrant discussion with the prescriber.

Months 4–12: maintenance phase

By month four, most patients are on the 2.4mg maintenance dose and the acute titration symptoms have largely resolved. The chronic side effect profile is meaningfully different from the titration profile.

Constipation often persists as the most common ongoing complaint. Some patients manage it with fiber and hydration alone. Others need ongoing osmotic laxative support.

Reduced taste preferences, particularly for greasy and very sweet foods, often becomes a stable feature rather than a side effect. Patients describe favorite foods losing appeal in ways that don't fully reverse.

Hair shedding — telogen effluvium — appears in a meaningful subset of patients in the 3–6 month range. This is associated with rapid weight loss generally rather than being a direct medication effect, and resolves over months once weight stabilizes. Adequate protein, iron, and zinc intake support hair recovery.

Muscle loss is the side effect with the longest tail. Without resistance training and adequate protein, lean mass can decrease substantially during the loss phase. This is why the lifestyle factors matter alongside the medication.

If side effects don't follow this pattern

Some patients have unusually rough titration experiences. Persistent nausea past month three, vomiting that doesn't resolve with dietary adjustment, fatigue that worsens rather than improves — these are reasons to discuss dose pauses, slower escalation schedules, or switching to tirzepatide (which some patients tolerate better) with the prescriber.

The titration schedule in the package insert is the default, not a fixed requirement. Many clinicians will hold patients at a lower dose for an additional month if symptoms warrant. This often resolves the issue without compromising eventual outcomes.

For patients considering whether to start, the pre-start checklist covers what is worth knowing in advance — including the predictable timing of the side effect window and the dietary and hydration adjustments that minimize it.

Key takeaways

• Weeks 1–4: dose is sub-therapeutic, side effects usually mild. Faint nausea and early fullness may emerge as the 0.5mg dose begins around week four.
• Weeks 5–8: usually the hardest window. Nausea peaks (around 40% of STEP 1 patients), constipation becomes prominent, vomiting affects a smaller subset.
• Weeks 9–16: counterintuitively, symptoms often ease even as the dose continues to climb. Body has adapted, dietary patterns have adjusted, appetite suppression deepens.
• Months 4–12: maintenance phase. Constipation often persists. Hair shedding (telogen effluvium) appears in a subset. Muscle loss is the longest-tail issue without resistance training.
• Red flags requiring clinical contact: severe abdominal pain (possible pancreatitis), persistent vomiting, signs of gallbladder disease, jaundice.
• Titration schedule is a default, not a fixed requirement. Slower escalation often resolves persistent symptoms without compromising outcomes.